What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.
Overview
Karin Eastham, a director of Veracyte (NASDAQ:VCYT), reported the sale of 3,729 shares of common stock in multiple open-market transactions on June 18, 2026, as detailed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($52.89); post-transaction value based on June 18, 2026 market close.
Details
* 1-year performance calculated using June 18, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.